Cowen
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Eric Assaraf
|
Employment |
5
|
1 |
HOUSE_OVERSIGHT_024921.jpg
This document is page 105 of a 'Cowen Collaborative Insights' report dated February 25, 2019. It serves as a 'Points of Contact' directory listing the profiles, contact information, and coverage areas for eleven Cowen research analysts. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024921', indicating it was produced during a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024920.jpg
This document is a financial chart produced by Cowen Collaborative Insights dated February 25, 2019. It details the rating history and stock performance of Canopy Growth Corporation from April 2016 to January 2019, including specific price targets. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, and is watermarked for Michael Cella of Cowen.
HOUSE_OVERSIGHT_024919.jpg
This document is page 103 of a financial report produced by Cowen on February 25, 2019. It displays 'Rating History' charts for three companies: GW Pharmaceuticals Plc, Tilray, and Turning Point Brands, showing stock prices versus target prices over time (2016-2019). The document is marked with the Bates stamp 'HOUSE_OVERSIGHT_024919' and notes it is intended for Michael Cella at Cowen.
HOUSE_OVERSIGHT_024917.jpg
This document is an addendum to a Cowen research report dated February 25, 2019, providing mandatory regulatory disclosures and certifications. It lists Canopy Growth, GW Pharmaceuticals, Tilray, and Turning Point Brands as subject companies and details Cowen's investment banking relationships, market making activities, and compensation policies related to these entities. The document also includes a standard disclaimer regarding the informational nature of the report, limitations of liability, and contact information for the compliance department.
HOUSE_OVERSIGHT_024916.jpg
This document appears to be page 100 of a financial research report produced by Cowen Collaborative Insights, dated February 25, 2019. It details valuation methodologies and investment risks specifically related to the U.S. and Canadian cannabis industries. The page bears a House Oversight Committee Bates stamp, suggesting it was part of a larger production of documents, likely related to financial investigations, though the text itself does not mention Jeffrey Epstein.
HOUSE_OVERSIGHT_024915.jpg
This document is page 99 of a report produced by Cowen Collaborative Insights, dated February 25, 2019. The content of the page is marked 'intentionally left blank,' though it includes a watermark restricting distribution to Michael Cella. The document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024914.jpg
This is page 98 of a Cowen Collaborative Insights report dated February 25, 2019. It is a placeholder page marked 'This page left blank intentionally' containing a watermark for Michael Cella and a House Oversight Bates stamp (024914).
HOUSE_OVERSIGHT_024913.jpg
This document is page 97 of a report produced by Cowen Collaborative Insights, dated February 25, 2019. It is an intentionally blank placeholder page containing a watermark identifying Michael Cella as the intended recipient and a Bates stamp indicating it is part of a House Oversight Committee production (HOUSE_OVERSIGHT_024913).
HOUSE_OVERSIGHT_024912.jpg
This document is page 96 of a financial research report titled 'Cowen Collaborative Insights' dated February 25, 2019. It contains 'Figure 136 Cannabis Comp Table,' an appendix listing market data and valuations for various cannabis-related companies such as Aphria Inc, Aurora Cannabis Inc, and Level Brands Inc. The document bears a 'HOUSE_OVERSIGHT_024912' stamp, indicating it was part of a document production to the House Oversight Committee, likely obtained from the files of Michael Cella at Cowen.
HOUSE_OVERSIGHT_024911.jpg
This document is page 95 of a financial research report by Cowen, dated February 25, 2019, analyzing the biodiesel market and biochemical CBD production methods. It details the economics of hemp biomass versus wood waste, provides data on biodiesel production inputs, and discusses Amyris's plans to produce CBD via sugarcane fermentation at their Brotas plant in Brazil following a $255 million agreement. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024909.jpg
Page 93 of a Cowen equity research report dated February 25, 2019. The text details clinical trial results for pharmaceutical companies GW and Zynerba regarding cannabinoid treatments (CBDV and ZYN002) for autism spectrum disorders, epilepsy, and Fragile X syndrome. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was included in a document production for a congressional investigation, though the specific page content is purely technical/medical market research.
HOUSE_OVERSIGHT_024907.jpg
This document is page 91 of a Cowen Collaborative Insights investment report dated February 25, 2019. It details the clinical trial results and investor analysis for the drug Epidiolex, specifically focusing on its efficacy in treating seizures (Dravet and LGS) with and without the concomitant use of clobazam, and noting that the drug is effective on its own. While part of a document production marked 'HOUSE_OVERSIGHT', the content is strictly pharmaceutical financial analysis and does not mention Jeffrey Epstein directly.
HOUSE_OVERSIGHT_024906.jpg
This document is page 90 of a Cowen equity research report dated February 25, 2019, analyzing the clinical trial results (GWPCARE3) for GW Pharma's drug Epidiolex. It contains statistical data, bar charts, and a safety table regarding seizure reduction and adverse effects. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production to the US House Oversight Committee, likely regarding financial records or communications involving the recipient or related parties.
HOUSE_OVERSIGHT_024905.jpg
This document is page 89 of a Cowen Collaborative Insights research report dated February 25, 2019. It provides a detailed analysis of Phase 3 clinical trials for the drug Epidiolex (produced by GW Pharma) for the treatment of Lennox-Gastaut syndrome (LGS), including trial designs, efficacy statistics regarding seizure reduction, and adverse event data. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was collected as part of a congressional investigation.
HOUSE_OVERSIGHT_024903.jpg
This document is page 87 of a 'Cowen Collaborative Insights' report dated February 25, 2019, analyzing the pharmaceutical market for cannabinoid-based drugs, specifically focusing on GW Pharmaceuticals' Epidiolex and its clinical trials for epilepsy. The text details statistical results from Phase III trials, FDA approval timelines, and efficacy comparisons against placebos. The document bears a 'HOUSE_OVERSIGHT_024903' stamp, indicating it was part of a document production for a congressional investigation, and is watermarked for Michael Cella at Cowen.
HOUSE_OVERSIGHT_024902.jpg
This document is page 86 of a Cowen 'Collaborative Insights' research report dated February 25, 2019, analyzing the cannabis market in Uruguay. It details corporate acquisitions of Uruguayan cannabis and hemp companies (ICC Labs, NettaGrowth, Inverell S.A.) by larger entities (Aurora, Khiron, Auxly) between 2016 and 2019. The document bears a House Oversight Bates stamp, indicating it was part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024900.jpg
This document is page 84 of a Cowen Collaborative Insights market research report dated February 25, 2019. It details the legal and business landscape of the medical cannabis industry in Chile and Colombia, listing various companies involved such as Dayacann, Tilray, and Canopy Growth. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was gathered as part of a congressional investigation, likely related to financial records or investment bank communications.
HOUSE_OVERSIGHT_024899.jpg
This page from a Cowen market research report, dated February 25, 2019, analyzes the regulatory environment and market trends for CBD and hemp products in Switzerland and France. It details Swiss regulations regarding cosmetic products and recent corporate consolidations (LGC Capital, Wayland, Creso Pharma), while noting France's status as a leading hemp cultivator despite strict government crackdowns on retail CBD sales. The document bears a House Oversight Committee stamp, suggesting it was part of a congressional document production.
HOUSE_OVERSIGHT_024898.jpg
This document is page 82 of a Cowen Collaborative Insights report dated February 25, 2019, analyzing the cannabis and hemp markets in Italy and Switzerland. It details regulatory environments, specifically the 'cannabis light' market in Italy and medical/tobacco substitute regulations in Switzerland, while listing various corporate investments and acquisitions (Wayland, Canopy, CROP). The document bears a 'HOUSE_OVERSIGHT_024898' Bates stamp, indicating it was part of a document production to the House Oversight Committee, likely included in a larger batch of financial records.
HOUSE_OVERSIGHT_024897.jpg
This document is page 81 of a Cowen Collaborative Insights market research report dated February 25, 2019, discussing the regulatory landscape for medical cannabis and CBD in Europe, specifically the UK and Italy. It details the legalization history, licensing requirements involving agencies like the MHRA and FSA, and market activities of companies like GW Pharmaceuticals, Tilray, Bedrocan, Canopy, and Aurora. The document bears a 'HOUSE_OVERSIGHT_024897' Bates stamp, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024893.jpg
This document is a page from a Cowen 'Collaborative Insights' market report dated February 25, 2019, bearing the Bates stamp HOUSE_OVERSIGHT_024893. It details regulatory crackdowns and guidance regarding CBD (cannabidiol) products in Maine, New York, and North Carolina, specifically noting that these states are aligning with FDA guidance to prohibit CBD in food additives while creating specific frameworks for supplements or topicals. While part of the House Oversight production (likely related to financial records), the text itself discusses cannabis industry regulations and does not mention Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024892.jpg
This document is page 76 of a Cowen Collaborative Insights report dated February 25, 2019. It details regulatory challenges and updates regarding CBD and hemp products, specifically focusing on FDA regulations and state-level legislation in California (Assembly Bill 2914). The document bears a 'HOUSE_OVERSIGHT' footer, suggesting it was part of a document production for a congressional investigation, though the content itself is strictly related to cannabis industry regulation and contains no direct mention of Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024891.jpg
This document is a market research report from Cowen Washington Research Group dated February 25, 2019, authored by Assaraf and watermarked for Michael Cella. It analyzes the regulatory landscape for CBD following the passage of the 2018 Farm Bill, specifically highlighting that while hemp was declassified, the FDA (under Commissioner Scott Gottlieb) retains authority over CBD products making health claims or used in food. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024889.jpg
This document is page 73 of a Cowen financial research report dated February 25, 2019, stamped with a House Oversight Bates number. It details business partnerships in the cannabis/CBD sector, specifically a revenue-sharing agreement between Tilray and Authentic Brands Group (ABG) involving the Nine West brand, and a retail distribution deal between DSW and Green Growth Brands. The document outlines financial terms, including a $100MM-$250MM investment by Tilray, and discusses market expansion opportunities for CBD wellness products.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity